With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
Deep pockets, a strong commitment to R&D and a world class 5G patent portfolio mean that whatever its current difficulties the Chinese telecoms business is set to be a major player for the long term
Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway
From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely
When it comes to litigation strategy, drug businesses have another option to consider in some cases thanks to recent rulings from the courts of England and Wales.
For years much of the focus on creating value from intellectual property has been on patents, but the emergence of a group of new technologies may help to rewrite the rules on monetisation. Patents will still play a crucial role but look set to become part of a broader mix of intangible assets in the discussion around value creation.
As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies
In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead
The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration